Royal Bank of Canada Sells 2,170 Shares of Petmed Express Inc (NASDAQ:PETS)

Royal Bank of Canada lessened its stake in shares of Petmed Express Inc (NASDAQ:PETS) by 2.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 107,516 shares of the company’s stock after selling 2,170 shares during the quarter. Royal Bank of Canada owned approximately 0.53% of Petmed Express worth $1,685,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Renaissance Technologies LLC lifted its position in Petmed Express by 15.6% during the 2nd quarter. Renaissance Technologies LLC now owns 1,914,915 shares of the company’s stock worth $30,007,000 after acquiring an additional 259,100 shares in the last quarter. Vanguard Group Inc. increased its holdings in Petmed Express by 11.4% during the 2nd quarter. Vanguard Group Inc. now owns 1,407,736 shares of the company’s stock worth $22,059,000 after purchasing an additional 143,496 shares during the last quarter. Man Group plc increased its holdings in Petmed Express by 84.4% during the 2nd quarter. Man Group plc now owns 490,754 shares of the company’s stock worth $7,690,000 after purchasing an additional 224,632 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Petmed Express by 2.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 456,011 shares of the company’s stock worth $7,146,000 after purchasing an additional 12,917 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in Petmed Express by 0.9% during the 2nd quarter. Northern Trust Corp now owns 297,594 shares of the company’s stock worth $4,663,000 after purchasing an additional 2,759 shares during the last quarter. Hedge funds and other institutional investors own 97.46% of the company’s stock.

In other news, Director Gian Fulgoni sold 12,000 shares of the firm’s stock in a transaction on Wednesday, October 23rd. The stock was sold at an average price of $26.45, for a total value of $317,400.00. Following the transaction, the director now directly owns 58,900 shares in the company, valued at approximately $1,557,905. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.00% of the stock is owned by company insiders.

NASDAQ:PETS traded up $0.02 during midday trading on Friday, reaching $23.14. 375,200 shares of the company traded hands, compared to its average volume of 767,348. The firm has a market capitalization of $456.96 million, a price-to-earnings ratio of 17.56 and a beta of 0.63. The company has a fifty day moving average price of $20.71 and a 200 day moving average price of $18.21. Petmed Express Inc has a twelve month low of $15.00 and a twelve month high of $29.35.

Petmed Express (NASDAQ:PETS) last announced its quarterly earnings data on Monday, October 21st. The company reported $0.33 EPS for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.07. The firm had revenue of $69.94 million for the quarter, compared to analyst estimates of $69.65 million. Petmed Express had a return on equity of 20.45% and a net margin of 9.62%. The business’s quarterly revenue was down 2.0% compared to the same quarter last year. During the same period last year, the company earned $0.52 EPS.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 15th. Shareholders of record on Monday, November 4th will be given a $0.27 dividend. The ex-dividend date is Friday, November 1st. This represents a $1.08 dividend on an annualized basis and a yield of 4.67%.

Several research firms have issued reports on PETS. TheStreet upgraded Petmed Express from a “c” rating to a “b-” rating in a report on Tuesday, October 22nd. ValuEngine upgraded Petmed Express from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Craig Hallum boosted their price target on Petmed Express from $15.00 to $20.00 and gave the company a “hold” rating in a report on Thursday, October 17th. Finally, BidaskClub upgraded Petmed Express from a “sell” rating to a “hold” rating in a report on Thursday, August 1st.

Petmed Express Company Profile

PetMed Express, Inc and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. It markets prescription and non-prescription pet medications, and other health products for dogs and cats directly to the consumers. The company offers non-prescription medications and supplies, including flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, such as heartworm preventative, flea and tick preventative, arthritis, thyroid, diabetes, pain, heart/blood pressure, and other specialty medications, as well as generic substitutes.

Further Reading: Cost of Debt

Institutional Ownership by Quarter for Petmed Express (NASDAQ:PETS)

Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News